S1 Ep213: What Does the Future Hold for Immune Effector Cell Therapies?
About this episode
Experts discuss the future of immune effector cell therapies following the National ICE-T Conference.
Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Barry Paul, MD, spoke with CancerNetwork® about high-level takeaways that emerged during the meeting. They discussed how CAR T-cell therapies, bispecific antibodies, and other novel modalities currently fit into the treatment paradigm across multiple myeloma, leukemia, lymphoma, and other hematologic oncology populations. The experts first discussed ideas from a session dedicated to innovations in CAR T cells and cellular therapies, with Mahmoudjafari emphasizing ongoing work exploring novel constructs such as dual-targeting chimeric antigen receptors (CARs) that may overcome antigen escape. According to Paul, a need remains for determining appropriate biomarkers to identify patients who are most likely to derive long-term benefit from agents like ciltacabtagene autoleucel (Carvykti). Regarding another session related to bispecific antibodies and T-cell–engaging agents, Mahmoudjafari described how many new off-the-shelf therapeutic options are challenging clinicians to rethink care delivery models that can provide both high acuity monitoring and outpatient…
More episodes of Oncology On The Go
- S1 Ep217: Integrating Exercise and Lifestyle Intervention Into Oncologic Therapy
- S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview
- S1 Ep215: Navigating The Dynamic Landscape of Stem Cell Transplantation
- S1 Ep214: Are Zedoresertib and Lunresertib an Efficacious Combo Across Solid Tumors?
- S1 Ep211: Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas
- S1 Ep210: Elevating Precision Medicine Across Different Oncologic Populations
Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.